Oncotherapy Science Inc. (30O)
Market Open
11 Aug, 07:31
XDUS 
€
0. 08
0
0%
€
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
- Eps
€ 0.08
Previous Close Want to track 30O and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
30O trading today higher at €0.08, an increase of 0% from yesterday's close, completing a monthly decrease of -2.5% or €0. Over the past 12 months, 30O stock lost -4.878%.
30O is not paying dividends to its shareholders.
The last earnings report, released on May 11, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Oncotherapy Science Inc. has completed 2 stock splits, with the recent split occurring on Sep 26, 2013.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on JPX (JPY).
30O Chart
Oncotherapy Science Inc. (30O) FAQ
What is the stock price today?
The current price is €0.08.
On which exchange is it traded?
Oncotherapy Science Inc. is listed on XDUS.
What is its stock symbol?
The ticker symbol is 30O.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Oncotherapy Science Inc. ever had a stock split?
Oncotherapy Science Inc. had 2 splits and the recent split was on Sep 26, 2013.
Oncotherapy Science Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Junichi Shimada CEO | XDUS Exchange | JP3202150003 ISIN |
| Japan Country | 54 Employees | - Last Dividend | 26 Sep 2013 Last Split | - IPO Date |
Overview
OncoTherapy Science, Inc., established in 2001 and based in Kawasaki, Japan, is a biopharmaceutical company dedicated to the research and development of innovative cancer treatments. The company's primary focus is on the discovery and advancement of antibody drugs, genome analysis of cancer, liquid biopsy technologies, and the development of new immunotherapy treatments. With its robust pipeline of potential treatments in various stages of clinical trials, OncoTherapy Science, Inc. aims to address a range of cancers through scientific innovation and dedication to improving patient outcomes.
Products and Services
The company's development pipeline includes a variety of promising compounds and therapies aimed at treating various types of cancers:
- OTS167: A small molecular compound that inhibits maternal embryonic leucine zipper kinase. It is currently in Phase I/II clinical trials for the treatment of acute myeloid leukemia and in Phase I clinical trials for the treatment of breast cancer.
- OTS964: This small molecule TOPK inhibitor is in the non-clinical stage of development, highlighting the company’s efforts in advancing treatment options in the pre-clinical phase.
- Cancer Peptide Vaccines:
- S-588410: Completed Phase III clinical trials for esophageal cancer and Phase II clinical trials for bladder cancer, signifying a major advance in peptide vaccine therapy for cancer.
- S-488210: In Phase I/II clinical trials for the treatment of head and neck cancer, representing the company's commitment to addressing this challenging disease.
- S-588210: Currently in Phase I clinical trials for the treatment of solid tumors, expanding the potential applications of peptide vaccines in oncology.
- OTSGC-A24: In Phase I clinical trials for the treatment of gastric cancer, demonstrating the company’s dedicated research in gastrointestinal malignancies.
- Antibody Drugs:
- OTSA101: An antibody drug in Phase I clinical trials for synovial sarcoma, showcasing the company’s exploration into rare cancers.
- Anti-Amyloid Beta Peptide Antibody: Completed Phase I clinical trials for Alzheimer's disease, highlighting the company’s venture into neurodegenerative diseases with a cancer research perspective.
Contact Information
Address: 1-2 Higashida-cho
Phone: 81 4 4201 6429
Website: https://www.oncotherapy.co.jp
